Oral Micronized Progesterone and Finasteride Interaction

Why This Combination Comes Up in Clinical Practice

Prescribers encounter the progesterone-finasteride question most often in three clinical scenarios: postmenopausal women using OMP for endometrial protection who also take finasteride for female-pattern hair loss, transgender women on feminizing hormone therapy, and men on testosterone replacement therapy (TRT) who add progesterone for sleep or neuroprotection while already taking finasteride for androgenetic alopecia.

The combination is not contraindicated by the FDA-approved Prometrium label, nor by the finasteride (Proscar) prescribing information. No black-box warning addresses their concurrent use. The interaction databases at Lexicomp and Clinical Pharmacology classify the combination as a "monitor" or "minor" interaction rather than "avoid" or "contraindicated." The concern is pharmacodynamic, meaning both agents act on the same hormonal axis, and combining them could produce additive DHT suppression beyond what either drug achieves alone [1][2].

A 2012 review in the Journal of Steroid Biochemistry and Molecular Biology demonstrated that progesterone and its 5-AR metabolites modulate androgenic signaling at multiple tissue levels, including prostate, skin, and the central nervous system [3]. Understanding this shared biology is the foundation for safe co-prescribing.

Mechanism of Interaction: Shared 5-Alpha Reductase Pathway

The interaction between OMP and finasteride is pharmacodynamic, not pharmacokinetic. They do not compete for the same CYP450 enzymes in a clinically meaningful way, and neither drug inhibits P-glycoprotein transport of the other.

Finasteride is a competitive inhibitor of 5-AR type II (and, at higher doses, type III). It blocks conversion of testosterone to DHT, reducing serum DHT by approximately 70% at the 5 mg dose and roughly 65% at the 1 mg dose, according to data from the Prostate Cancer Prevention Trial (PCPT, N=18,882) [4]. Oral micronized progesterone, meanwhile, is itself a substrate for 5-AR. The enzyme converts progesterone into 5-alpha-dihydroprogesterone and then into allopregnanolone, a potent neurosteroid responsible for many of OMP's sedative and anxiolytic properties [5].

Here is where the overlap matters. Progesterone competes with testosterone for 5-AR binding. A 2003 study published in Endocrinology showed that supraphysiologic progesterone concentrations reduced DHT formation in prostate tissue homogenates by 15 to 30%, acting as a weak competitive substrate-inhibitor of the same enzyme finasteride targets [6]. When finasteride is already blocking 5-AR, the addition of progesterone may further reduce residual DHT production, but it also means less progesterone gets converted to allopregnanolone.

The net clinical effect: patients on both drugs may experience greater DHT suppression than intended, and they may derive less neurosteroid benefit from their progesterone dose than they would without finasteride present.

Pharmacokinetic Considerations: Metabolism Is Largely Independent

OMP is metabolized primarily by CYP2C19, CYP3A4, and CYP2C9 through hepatic first-pass metabolism, yielding pregnanediol glucuronide as the principal urinary metabolite [7]. Finasteride undergoes hepatic metabolism via CYP3A4, producing inactive metabolites excreted in urine and feces [2].

Both drugs use CYP3A4, but neither is a strong inhibitor or inducer of this enzyme. The theoretical risk of competitive CYP3A4 inhibition raising plasma levels of either drug has not been demonstrated in published pharmacokinetic studies. A 1999 analysis of progesterone pharmacokinetics noted that CYP3A4 inhibitors like ketoconazole can raise OMP levels by 2- to 4-fold, but finasteride lacks meaningful CYP3A4 inhibitory activity at therapeutic doses [7].

No dose adjustment based on pharmacokinetic interaction is required. The clinical focus should remain on the pharmacodynamic overlap described above.

Clinical Severity: What the Evidence Actually Shows

No randomized controlled trial has directly studied OMP plus finasteride as a combination. The evidence base consists of mechanistic pharmacology studies, case series in transgender medicine, and extrapolation from trials of each drug independently.

The Endocrine Society's 2017 Clinical Practice Guideline for transgender care references combination anti-androgen regimens that include progesterone alongside 5-AR inhibitors, noting that "providers should monitor serum testosterone and estradiol levels every 3 months during the first year" when multiple agents affecting androgen metabolism are used [8]. While this guideline addresses transgender women specifically, the monitoring principle applies broadly.

In the hair-loss context, a 2019 systematic review in Dermatology and Therapy assessed finasteride safety across 4,379 patients and found that the most common adverse effects (decreased libido at 1.5 to 6%, erectile dysfunction at 1.3 to 3.4%) were dose-dependent and correlated with the degree of DHT suppression [9]. Adding another DHT-lowering agent, even a weak one like progesterone, could theoretically shift some patients from subclinical to symptomatic androgen deficiency.

Dr. Shalender Bhasin, Professor of Medicine at Harvard Medical School and principal investigator on multiple androgen physiology trials, wrote in a 2018 Journal of Clinical Endocrinology & Metabolism editorial: "The clinical significance of drug interactions affecting the androgen axis depends less on the mechanism and more on the cumulative magnitude of DHT suppression in a given patient" [10].

Monitoring Protocol for Co-Prescribed Patients

Patients taking both OMP and finasteride should follow a structured monitoring plan. The goal is catching excessive androgen suppression before it becomes symptomatic.

Baseline (before adding the second drug):

• Serum DHT
• Total testosterone
• Free testosterone (calculated or equilibrium dialysis)
• Sex hormone-binding globulin (SHBG)
• Complete metabolic panel including hepatic function

Follow-up at 6 weeks, then every 3 to 6 months:

• Repeat DHT and testosterone panel
• Screen for new-onset sexual dysfunction using a validated instrument (FSFI for women, IIEF-5 for men)
• Assess sleep quality (since allopregnanolone production may be reduced)
• Monitor for mood changes, particularly depressive symptoms, given allopregnanolone's role in GABA-A receptor modulation [5]

The American Association of Clinical Endocrinologists (AACE) 2020 guidelines on hormone replacement recommend checking liver function tests at baseline and annually for patients on oral progesterone, since hepatic first-pass metabolism produces high portal concentrations of progesterone metabolites [11]. This recommendation holds regardless of finasteride use but gains added importance when multiple hepatically metabolized agents are combined.

Dose-Adjustment Strategies

No formal dose-reduction protocol exists for this combination. Practical adjustments are guided by lab values and symptoms.

If serum DHT drops below the lower limit of the reference range (typically <5 ng/dL in men) after combining both drugs, the prescriber has three options. First, reduce the finasteride dose. The 1 mg dose already achieves near-maximal scalp DHT reduction, and some clinicians use 0.5 mg or 0.25 mg with evidence of maintained efficacy in hair preservation [12]. Second, switch from oral to vaginal progesterone, which bypasses hepatic first-pass metabolism and reduces systemic 5-AR substrate competition. A 2005 study in Fertility and Sterility showed that vaginal micronized progesterone achieved equivalent endometrial protection with only 25 to 33% of the systemic exposure compared to oral administration [13]. Third, space the dosing. Taking OMP at bedtime and finasteride in the morning maximizes the temporal separation of peak plasma concentrations (OMP Tmax = 2 to 3 hours; finasteride Tmax = 1 to 2 hours), though this approach has no direct trial evidence supporting improved outcomes.

For transgender women on complex regimens that include estradiol, spironolactone, progesterone, and finasteride, the UCSF Transgender Care guidelines recommend consolidating androgen blockade into the fewest agents possible. If finasteride is added for hairline preservation, re-evaluate whether the progesterone dose needs reduction from 200 mg to 100 mg, or whether spironolactone (another anti-androgen) can be tapered [8].

Special Populations and Risk Factors

Pregnancy. Both drugs are Category X. Finasteride causes feminization of male fetal genitalia at doses well below the therapeutic range. OMP is used therapeutically in early pregnancy for luteal support but not in combination with finasteride under any circumstance. Women of reproductive potential taking both drugs must use reliable contraception [2].

Hepatic impairment. Patients with Child-Pugh class B or C liver disease have impaired first-pass metabolism of OMP, leading to higher systemic exposure and prolonged half-life. The Prometrium label advises caution in liver disease. Adding finasteride to a hepatically impaired patient already on OMP increases the pharmacodynamic interaction risk because more unmetabolized progesterone reaches systemic circulation and competes with testosterone for 5-AR [1].

CYP2C19 poor metabolizers. Approximately 2 to 5% of Caucasians and 15 to 20% of East Asian populations are CYP2C19 poor metabolizers, according to PharmGKB data [14]. These individuals metabolize OMP more slowly, resulting in higher peak concentrations and greater 5-AR substrate competition. If pharmacogenomic testing reveals CYP2C19 poor-metabolizer status, consider vaginal progesterone to bypass the affected hepatic pathway.

Older adults. Men over 65 already have declining DHT levels. The PCPT demonstrated that finasteride reduced prostate cancer risk by 24.8% over 7 years but was associated with a small increase in high-grade tumors (6.4% vs. 5.1% in the placebo group) [4]. Adding another DHT-lowering agent in this population requires careful risk-benefit discussion with the patient.

Allopregnanolone: The Hidden Variable

One underappreciated consequence of this combination involves allopregnanolone, the neurosteroid metabolite of progesterone. Allopregnanolone acts as a positive allosteric modulator of GABA-A receptors, producing anxiolytic, sedative, and antidepressant effects. The FDA approved brexanolone (Zulresso), a synthetic allopregnanolone, for postpartum depression in 2019 based on two Phase 3 trials showing remission rates of 51% and 50% [15].

When finasteride blocks 5-AR, it reduces conversion of progesterone to allopregnanolone. A 2017 study in Psychoneuroendocrinology (N=16 healthy men) demonstrated that finasteride 5 mg daily reduced cerebrospinal fluid allopregnanolone concentrations by approximately 75% within 30 days [16]. Patients who take OMP specifically for its sleep-promoting or mood-stabilizing neurosteroid effects may find those benefits diminished when finasteride is added.

If a patient reports worsened insomnia or mood after starting finasteride while already on OMP, reduced allopregnanolone production should be considered as a possible cause before attributing the symptoms to other factors.

Counseling Points for Patients

Patients should understand five concrete points before starting both medications together. The two drugs are not dangerous to combine, but they affect the same hormonal system. Blood work is needed before starting and every 3 to 6 months after. Sexual side effects from finasteride might be somewhat more likely if progesterone is also lowering DHT. The sleep and calming benefits of progesterone may be reduced because finasteride partially blocks the enzyme that creates the active sleep-promoting metabolite. Any new symptoms (mood changes, reduced libido, breast tenderness, or fatigue) should be reported promptly so the prescriber can adjust doses rather than discontinue either medication abruptly.

Patients should be specifically warned against stopping OMP abruptly if they are using it for endometrial protection on estrogen therapy, as this creates unopposed estrogen exposure and endometrial hyperplasia risk. The North American Menopause Society (NAMS) 2022 position statement recommends a minimum of 12 to 14 days per month of progestogen exposure in women with an intact uterus taking systemic estrogen [17].